AU4534593A - Compositions and methods for enhanced drug delivery - Google Patents

Compositions and methods for enhanced drug delivery

Info

Publication number
AU4534593A
AU4534593A AU45345/93A AU4534593A AU4534593A AU 4534593 A AU4534593 A AU 4534593A AU 45345/93 A AU45345/93 A AU 45345/93A AU 4534593 A AU4534593 A AU 4534593A AU 4534593 A AU4534593 A AU 4534593A
Authority
AU
Australia
Prior art keywords
compositions
methods
drug delivery
enhanced drug
enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45345/93A
Inventor
Ron L Hale
Amy Lu
Kevin R Oldenburg
Harold E Selick
Dennis Solas
Alejandro C Zaffaroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymax Technologies NV
Original Assignee
Affymax Technologies NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Technologies NV filed Critical Affymax Technologies NV
Publication of AU4534593A publication Critical patent/AU4534593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
AU45345/93A 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery Abandoned AU4534593A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89821992A 1992-06-12 1992-06-12
US898219 1992-06-12
US946393A 1993-01-27 1993-01-27
US009463 1993-01-27
PCT/US1993/005631 WO1993025197A1 (en) 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery

Publications (1)

Publication Number Publication Date
AU4534593A true AU4534593A (en) 1994-01-04

Family

ID=26679515

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45345/93A Abandoned AU4534593A (en) 1992-06-12 1993-06-11 Compositions and methods for enhanced drug delivery

Country Status (3)

Country Link
EP (1) EP0647133A4 (en)
AU (1) AU4534593A (en)
WO (1) WO1993025197A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
DK0688333T3 (en) * 1993-03-10 1999-02-08 Magainin Pharma Steroid derivatives, pharmaceutical compositions containing them and their use as antibiotics or disinfectants
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
US6468981B1 (en) 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
FR2727117A1 (en) * 1994-11-18 1996-05-24 Geffard Michel USE OF POLYLYSIN CONJUGATES FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DEGENERATIVE DISORDERS OF AUTOIMMUN CHARACTER
NZ302723A (en) † 1995-03-02 1998-04-27 Scherer Ltd R P Composition comprising monoamine oxidase b inhibitor and a carrier formulated for pre-gastric absorption of the monoamine oxidase b inhibitor
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5747453A (en) * 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
IT1285405B1 (en) * 1995-06-06 1998-06-03 Alza Corp MODIFICATION OF POLYPEPTIDE DRUGS TO INCREASE FLOW BY ELECTROTRANSPORT.
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5994336A (en) * 1995-06-07 1999-11-30 Magainin Pharmaceuticals Inc. Method of inhibiting proliferation of cells by administering an aminosterol compound
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
IT1283955B1 (en) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti BIS ALCANOIL ESTERS OF CARNITINE WITH ANTIBACTERIAL, ANTIMICOTIC AND ANTIPROTZOARY ACTIVITY.
WO1997040835A1 (en) * 1996-04-26 1997-11-06 Magainin Pharmaceuticals Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
IT1299266B1 (en) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti REVERSIBLE CARNITINE PALMITOIL INHIBITORS TRANSFERRED
DE60123939T2 (en) 2000-04-12 2007-05-31 Genaera Corp. A PROCESS FOR THE PREPARATION OF 7.ALPHA.-HYDROXY 3-AMINO-SUBSTITUTED STEROL COMPOUNDS, WITHOUT PROTECTION OF THE 7.ALPHA.-HYDROXY GROUP
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
GB0116047D0 (en) * 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
DE10303669A1 (en) * 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. New quaternary ammonioalkyl carbonate esters useful for treating bacterial and fungal infections and potentially useful for regulating cholesterol biosynthesis
CN101068538A (en) 2004-11-04 2007-11-07 什诺波特有限公司 Gaba analog prodrug sustained release oral dosage forms
JP5227593B2 (en) * 2005-02-04 2013-07-03 アメリカ合衆国 Nandrolone 17β-carbonate
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US7531572B2 (en) 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
CN101522692A (en) * 2006-10-11 2009-09-02 于崇曦 Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
ES2607901T3 (en) 2007-01-31 2017-04-04 Chongxi Yu Water-soluble prodrugs positively charged with 1H-imidazo [4,5-c] quinolin-4-amines and compounds related to very high skin penetration rats
JP5276020B2 (en) * 2007-02-13 2013-08-28 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ Cationic estradiol derivative, synthesis method thereof, and pharmaceutical composition
RU2509076C2 (en) 2007-06-04 2014-03-10 Текфилдз Инк Prodrugs of nonsteroid anti-inflammatory agents (nsaia) with very high speed of penetration through skin and membranes, and new medical applications of above said prodrugs
EP2219587A4 (en) * 2007-11-14 2012-11-21 Univ California Sterol-modified amphiphilic lipids
KR101753296B1 (en) 2008-12-04 2017-07-03 충시 위 High Penetration Compositions and Their Applications
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2786465C (en) 2010-01-15 2018-09-25 Suzhou Neupharma Co., Ltd. Bufalin derivatives for the treatment of cancer
JP5848761B2 (en) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Prodrugs of NH acidic compounds: derivatives of esters, carbonates, carbamates and phosphonates
WO2012027957A1 (en) 2010-08-28 2012-03-08 Suzhou Neupharma Co., Ltd. Bufalin derivatives, pharmaceutical compositions and use thereof
EP2670763B1 (en) * 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certain chemical entities, compositions, and methods
EP3156056B1 (en) 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
CN103607888A (en) * 2011-04-08 2014-02-26 斯法尔制药私人有限公司 Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
EP2790734B1 (en) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
JP6219918B2 (en) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
EP3453713B1 (en) 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
JP6654042B2 (en) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition with improved storage stability
CN103896791B (en) * 2012-12-25 2016-12-28 广东隆赋药业股份有限公司 The preparation method of acetyl levocarnitine hydrochlorate
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
CA2943213C (en) 2014-03-20 2022-07-05 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN104151452B (en) * 2014-07-16 2017-02-01 西北大学 Poly(N-(2-hydroxypropyl)methacrylamide)-lonidamine macromolecular prodrug and preparation method thereof
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN115851076B (en) * 2022-12-21 2023-10-31 湖北航天化学技术研究所 Graphene zinc-containing antirust paint and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023206A1 (en) * 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Antiinflammatory indomethacin di:alkylamino-ethyl ester derivs. - prepd. by heating indomethacin with an O-di:alkyl:aminoethyl-N,N'-di:isopropyl isourea in benzene
US4386026A (en) * 1981-04-20 1983-05-31 Merck & Co., Inc. Cell-specific glycopeptide ligands
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
JPS6452742A (en) * 1987-04-27 1989-02-28 Syntex Pharma Int Omega-quaternary ammonium alkyl ester and thioester of acidic non-steroidal antiinflammatory
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane
CA2072360A1 (en) * 1989-12-26 1991-06-27 Abraham J. Domb Prodrug anhydride compositions

Also Published As

Publication number Publication date
EP0647133A4 (en) 1997-10-29
WO1993025197A1 (en) 1993-12-23
EP0647133A1 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
AU4534593A (en) Compositions and methods for enhanced drug delivery
ZA942804B (en) Oral drug delivery compositions and methods
AU4989993A (en) Drug delivery system
AU664807B2 (en) Drug delivery system
AU8935591A (en) Drug delivery system and method
IL110588A (en) Bioadhesive emulsion preparations for enhanced drug delivery
AU7673694A (en) Simultaneous angioplasty and drug delivery
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
AU4227793A (en) Drug infuser
AU2157192A (en) 4-aminoquinolines and pharmaceutical compositions thereof
HUP0000474A3 (en) Arylethenesulfonamide derivatives and drug composition containing the same
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
AU3716193A (en) Pharmaceutical compositions
AU5100393A (en) Diindolo compounds and pharmaceutical compositions containing them
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
AU6285194A (en) Stabilised pharmaceutical compositions and methods for preparing same
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
AU1227292A (en) Pharmaceutical antitussive compositions
AU1432292A (en) Drug delivery composition and method of using the same
AU7275894A (en) Imidazolylalkylamine derivative and pharmaceutical composition thereof
AU2587195A (en) Growth hormone therapy and related methods and pharmaceutical compositions
GB9501286D0 (en) Pharmaceutical compositions and preparations thereof
AU6690394A (en) Imidazolylquinoxalinedione derivative and pharmaceutical composition thereof
HUP9802291A3 (en) Penicillaminamide derivatives and pharmaceutical compositions containing them
AU3710695A (en) Quinolonylcarboxyerythromycin derivatives and pharmaceutical compositions containing them